WO1998007447B1 - Anticonvulsant containing composition for treating neuropathic pain - Google Patents
Anticonvulsant containing composition for treating neuropathic painInfo
- Publication number
- WO1998007447B1 WO1998007447B1 PCT/US1997/014680 US9714680W WO9807447B1 WO 1998007447 B1 WO1998007447 B1 WO 1998007447B1 US 9714680 W US9714680 W US 9714680W WO 9807447 B1 WO9807447 B1 WO 9807447B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- analgesic
- sodium
- member selected
- group
- anticonvulsant
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 5
- 230000001773 anti-convulsant Effects 0.000 title claims abstract 3
- 239000001961 anticonvulsive agent Substances 0.000 title claims abstract 3
- 208000004296 Neuralgia Diseases 0.000 title abstract 2
- 230000003000 nontoxic Effects 0.000 claims abstract 4
- 231100000252 nontoxic Toxicity 0.000 claims abstract 4
- CXOFVDLJLONNDW-UHFFFAOYSA-N Epinat Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 6
- NIJJYAXOARWZEE-UHFFFAOYSA-N Depacane Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 5
- 229960000604 valproic acid Drugs 0.000 claims 5
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 4
- 229960002036 Phenytoin Drugs 0.000 claims 4
- 230000000202 analgesic Effects 0.000 claims 4
- 239000000730 antalgic agent Substances 0.000 claims 4
- 230000001225 therapeutic Effects 0.000 claims 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1H-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 2
- XKSAJZSJKURQRX-UHFFFAOYSA-N 2-acetyloxy-5-(4-fluorophenyl)benzoic acid Chemical compound C1=C(C(O)=O)C(OC(=O)C)=CC=C1C1=CC=C(F)C=C1 XKSAJZSJKURQRX-UHFFFAOYSA-N 0.000 claims 2
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan zwitterion Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 claims 2
- 229940022659 Acetaminophen Drugs 0.000 claims 2
- BZKPWHYZMXOIDC-UHFFFAOYSA-N Acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 claims 2
- CXOXHMZGEKVPMT-UHFFFAOYSA-N Clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 claims 2
- DGBIGWXXNGSACT-UHFFFAOYSA-N Clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims 2
- MKXZASYAUGDDCJ-SZMVWBNQSA-N Dextromethorphan Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims 2
- 229960001985 Dextromethorphan Drugs 0.000 claims 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N Diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims 2
- 229940064790 Dilantin Drugs 0.000 claims 2
- 229940028937 Divalproex Sodium Drugs 0.000 claims 2
- 229960005293 Etodolac Drugs 0.000 claims 2
- XFBVBWWRPKNWHW-UHFFFAOYSA-N Etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims 2
- 229950007979 FLUFENISAL Drugs 0.000 claims 2
- ZPAKPRAICRBAOD-UHFFFAOYSA-N Fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 claims 2
- 229960001419 Fenoprofen Drugs 0.000 claims 2
- RDJGLLICXDHJDY-UHFFFAOYSA-N Fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 claims 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 2
- 229960000905 Indomethacin Drugs 0.000 claims 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N Ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims 2
- 229940098829 Magnesium Sulfate Injection Drugs 0.000 claims 2
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims 2
- HYYBABOKPJLUIN-UHFFFAOYSA-N Mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims 2
- 229960002057 Metharbital Drugs 0.000 claims 2
- FWJKNZONDWOGMI-UHFFFAOYSA-N Metharbital Chemical compound CCC1(CC)C(=O)NC(=O)N(C)C1=O FWJKNZONDWOGMI-UHFFFAOYSA-N 0.000 claims 2
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 2
- OFPXSFXSNFPTHF-UHFFFAOYSA-N Oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 claims 2
- 229960002888 Oxitriptan Drugs 0.000 claims 2
- 229960003274 Paramethadione Drugs 0.000 claims 2
- VQASKUSHBVDKGU-UHFFFAOYSA-N Paramethadione Chemical compound CCC1(C)OC(=O)N(C)C1=O VQASKUSHBVDKGU-UHFFFAOYSA-N 0.000 claims 2
- XPFRXWCVYUEORT-UHFFFAOYSA-N Phenacemide Chemical compound NC(=O)NC(=O)CC1=CC=CC=C1 XPFRXWCVYUEORT-UHFFFAOYSA-N 0.000 claims 2
- 229960002895 Phenylbutazone Drugs 0.000 claims 2
- 229960002790 Phenytoin sodium Drugs 0.000 claims 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 2
- IBALRBWGSVJPAP-HEHNFIMWSA-N Progabide Chemical compound C=1C(F)=CC=C(O)C=1C(=N/CCCC(=O)N)/C1=CC=C(Cl)C=C1 IBALRBWGSVJPAP-HEHNFIMWSA-N 0.000 claims 2
- 229960000894 Sulindac Drugs 0.000 claims 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N Sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 2
- HMHVCUVYZFYAJI-UHFFFAOYSA-N Sultiame Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1S(=O)(=O)CCCC1 HMHVCUVYZFYAJI-UHFFFAOYSA-N 0.000 claims 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N Tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims 2
- IRYJRGCIQBGHIV-UHFFFAOYSA-N Trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 claims 2
- 229960004453 Trimethadione Drugs 0.000 claims 2
- ZXVNMYWKKDOREA-UHFFFAOYSA-N Zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 claims 2
- 229960000571 acetazolamide Drugs 0.000 claims 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 2
- 229960001403 clobazam Drugs 0.000 claims 2
- 229960003120 clonazepam Drugs 0.000 claims 2
- 229960001259 diclofenac Drugs 0.000 claims 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 2
- 229960000616 diflunisal Drugs 0.000 claims 2
- -1 famotodine Chemical compound 0.000 claims 2
- 229960001395 fenbufen Drugs 0.000 claims 2
- 229960002390 flurbiprofen Drugs 0.000 claims 2
- 229960001680 ibuprofen Drugs 0.000 claims 2
- 229960000991 ketoprofen Drugs 0.000 claims 2
- 229960004752 ketorolac Drugs 0.000 claims 2
- 229960003803 meclofenamic acid Drugs 0.000 claims 2
- 229960003464 mefenamic acid Drugs 0.000 claims 2
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N nabumeton Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims 2
- 229960004270 nabumetone Drugs 0.000 claims 2
- 229960002009 naproxen Drugs 0.000 claims 2
- 229960002739 oxaprozin Drugs 0.000 claims 2
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- 229960005489 paracetamol Drugs 0.000 claims 2
- 229960003396 phenacemide Drugs 0.000 claims 2
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims 2
- 229960002702 piroxicam Drugs 0.000 claims 2
- 229960002752 progabide Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 claims 2
- 229940032342 sulthiame Drugs 0.000 claims 2
- 229960002573 sultiame Drugs 0.000 claims 2
- 229960001017 tolmetin Drugs 0.000 claims 2
- 229960003414 zomepirac Drugs 0.000 claims 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N Amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 Amantadine Drugs 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N Carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- JAQUASYNZVUNQP-PVAVHDDUSA-N Dextrorphan Chemical compound C1C2=CC=C(O)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 JAQUASYNZVUNQP-PVAVHDDUSA-N 0.000 claims 1
- 229950006878 Dextrorphan Drugs 0.000 claims 1
- 229960003533 Ethotoin Drugs 0.000 claims 1
- SZQIFWWUIBRPBZ-UHFFFAOYSA-N Ethotoin Chemical compound O=C1N(CC)C(=O)NC1C1=CC=CC=C1 SZQIFWWUIBRPBZ-UHFFFAOYSA-N 0.000 claims 1
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapen Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N Lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N Memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 229960000906 Mephenytoin Drugs 0.000 claims 1
- GMHKMTDVRCWUDX-UHFFFAOYSA-N Mephenytoin Chemical compound C=1C=CC=CC=1C1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-UHFFFAOYSA-N 0.000 claims 1
- 229940041659 Mephobarbital Drugs 0.000 claims 1
- AJXPJJZHWIXJCJ-UHFFFAOYSA-N Mesuximide Chemical compound O=C1N(C)C(=O)CC1(C)C1=CC=CC=C1 AJXPJJZHWIXJCJ-UHFFFAOYSA-N 0.000 claims 1
- ALARQZQTBTVLJV-UHFFFAOYSA-N Methylphenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)N(C)C1=O ALARQZQTBTVLJV-UHFFFAOYSA-N 0.000 claims 1
- 229960002695 Phenobarbital Drugs 0.000 claims 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N Phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims 1
- WLWFNJKHKGIJNW-UHFFFAOYSA-N Phensuximide Chemical compound O=C1N(C)C(=O)CC1C1=CC=CC=C1 WLWFNJKHKGIJNW-UHFFFAOYSA-N 0.000 claims 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N Primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 claims 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 229960001848 lamotrigine Drugs 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- 229960003477 methsuximide Drugs 0.000 claims 1
- 229960001703 methylphenobarbital Drugs 0.000 claims 1
- 229960004227 phensuximide Drugs 0.000 claims 1
- 229960002393 primidone Drugs 0.000 claims 1
- 229960004394 topiramate Drugs 0.000 claims 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N NMDA Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
- 102000004868 N-methyl-D-aspartate receptors Human genes 0.000 abstract 1
- 108090001041 N-methyl-D-aspartate receptors Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000003042 antagnostic Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000003834 intracellular Effects 0.000 abstract 1
- 230000002981 neuropathic Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Abstract
Composition for alleviating neuropathic pain which a neuropathic pain-alleviating amount of an anticonvulsant is combined with an anticonvulsant-potentiating amount of a nontoxic antagonist, or blocker, for the N-methyl-D-aspartate (NMDA) receptor or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation.
Claims
AMENDED CLAIMS
[received by the International Bureau on 10 February 1998 (10.02.98); new claims 14-19 added; remaining claims unchanged (2 pages)]
trimethadione, benzodiazepine, phenacemide, acetazolamide, progabide, clonazepam, divalproex sodium, magnesium sulfate injection, metharbital, paramethadione, phenytoin sodium, valproate sodium, clobazam, sulthiame, dilantin, diphenylan and L-5-hydroxytryptophan and nontoxic NMDA receptor blocker (b) is at least one member selected from the group consisting of dextromethorphan, dextrorphan, amantadine, memantine and pharmaceutically acceptable salt thereof and (a) and (b) are coadministered as a single dosage unit. 13. The method of claim 8 wherein anticonvulsant
(a) is at least one member selected from the group consisting of lamotrigine, gabapentin, valproic acid, topiramate, famotodine, phenobarbital, diphenylhydantoin, phenytoin, mephenytoin, ethotoin, mephobarbital , primidone, carbamazepine, ethosuximi-de , methsuximide, phensuximide, trimethadione, benzodiazepine, phenacemide, acetazolamide, progabide, clonazepam, divalproex sodium, magnesium sulfate injection, metharbital, paramethadione, phenytoin sodium, valproate sodium, clobazam, sulthiame, dilantin, diphenylan and L-5-hydroxytryptophan and nontoxic NMDA receptor blocker
(b) is dextromethorphan, or pharmaceutically acceptable salt thereof .
14. The therapeutic composition of Claim 1 further comprising (c) an analgesic. 15. The therapeutic composition of Claim 14 wherein the analgesic is a non-narcotic analgesic.
16. The therapeutic composition of Claim 15 wherein the non-narcotic analgesic is at least one member selected from the group consisting of acetaminophen, aspirin, diclofenac, diflusinal, etodolac, fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tolmetin and zomepirac
17. The method of Claim 8 further comprising (c) an analgesic.
18. The method of Claim 17 wherein the analgesic is a non-narcotic analgesic.
19. The method of Claim 18 wherein the non- narcotic analgesic is at least one member selected from the group consisting of ace taminophen, aspirin, diclofenac, diflusinal, etodolac, fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tolmetin and zomepirac.
1 7
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002264182A CA2264182A1 (en) | 1996-08-23 | 1997-08-21 | Anticonvulsant containing composition for treating neuropathic pain |
| AU40788/97A AU4078897A (en) | 1996-08-23 | 1997-08-21 | Anticonvulsant containing composition for treating neuropathic pain |
| DE69733081T DE69733081T2 (en) | 1996-08-23 | 1997-08-21 | ANTICONVULSIVE PREPARATION FOR THE TREATMENT OF NEUROPATHIC PAIN |
| AT97938475T ATE293458T1 (en) | 1996-08-23 | 1997-08-21 | PREPARATION CONTAINING ANTICONVULSIVE AGENTS FOR THE TREATMENT OF NEUROPATHIC PAIN |
| EP97938475A EP0942752B1 (en) | 1996-08-23 | 1997-08-21 | Anticonvulsant containing composition for treating neuropathic pain |
| JP10510942A JP2001500121A (en) | 1996-08-23 | 1997-08-21 | Anticonvulsants comprising a composition for treating neuropathic pain |
| US09/253,598 US6187338B1 (en) | 1996-08-23 | 1999-02-22 | Anticonvulsant containing composition for treating neuropathic pain |
| US09/780,858 US6406716B2 (en) | 1996-08-23 | 2001-02-09 | Anticonvulsant containing composition for treating neuropathic pain |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2450896P | 1996-08-23 | 1996-08-23 | |
| US60/024,508 | 1996-08-23 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/253,598 Continuation US6187338B1 (en) | 1996-08-23 | 1999-02-22 | Anticonvulsant containing composition for treating neuropathic pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1998007447A1 WO1998007447A1 (en) | 1998-02-26 |
| WO1998007447B1 true WO1998007447B1 (en) | 1998-03-26 |
Family
ID=21820954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/014680 WO1998007447A1 (en) | 1996-08-23 | 1997-08-21 | Anticonvulsant containing composition for treating neuropathic pain |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6187338B1 (en) |
| EP (1) | EP0942752B1 (en) |
| JP (1) | JP2001500121A (en) |
| AT (1) | ATE293458T1 (en) |
| AU (1) | AU4078897A (en) |
| CA (1) | CA2264182A1 (en) |
| DE (1) | DE69733081T2 (en) |
| ES (1) | ES2241055T3 (en) |
| WO (1) | WO1998007447A1 (en) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4078897A (en) * | 1996-08-23 | 1998-03-06 | Algos Pharmaceutical Corporation | Anticonvulsant containing composition for treating neuropathic pain |
| AU8668598A (en) | 1997-08-20 | 1999-03-08 | University Of Oklahoma, The | Gaba analogs to prevent and treat gastrointestinal damage |
| ES2253825T3 (en) | 1997-09-08 | 2006-06-01 | Warner-Lambert Company Llc | ANALGESIC COMPOSITIONS THAT INCLUDE ANTIEPILEPTIC COMPOUNDS AND PROCEDURES FOR USING THE SAME. |
| AU784225B2 (en) * | 1997-09-08 | 2006-02-23 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| AU2002301362B8 (en) * | 1997-09-08 | 2006-05-04 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| PL345340A1 (en) * | 1998-07-09 | 2001-12-17 | Warner Lambert Co | Compositions comprising gaba analogs and caffeine |
| US6309858B1 (en) | 1998-09-29 | 2001-10-30 | Syntex (U.S.A.) Llc | T-type calcium channel variants; compositions thereof; and uses |
| US6191142B1 (en) * | 1999-02-18 | 2001-02-20 | Ortho-Mcneil Pharmaceutical, Inc. | Aroyl aminoacyl pyrroles for use in the treatment of neuropathic pain |
| WO2000053225A1 (en) * | 1999-03-10 | 2000-09-14 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| JP2002541215A (en) * | 1999-04-09 | 2002-12-03 | ユーロ−セルティック エス． ア． | Sodium channel blocker compositions and uses thereof |
| WO2001000191A2 (en) * | 1999-06-23 | 2001-01-04 | Warner-Lambert Company | Use of fosphenytion for the treatment of acute neuropathic pain |
| ES2234651T3 (en) * | 1999-08-20 | 2005-07-01 | Ortho-Mcneil Pharmaceutical, Inc. | COMPOSITION THAT INCLUDES A TRAMADOL MATTER AND AN ANTI-CONVULSIVE PHARMACO. |
| WO2002002521A2 (en) | 2000-06-30 | 2002-01-10 | Ortho-Mcneil Pharmaceutical, Inc. | Aroyl aminoacyl pyrrole compounds and their pharmaceutical use |
| US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| EP1436258A4 (en) * | 2001-03-08 | 2005-03-23 | Univ Emory | Ph-dependent nmda receptor antagonists |
| ES2357808T3 (en) | 2001-06-07 | 2011-04-29 | Christine Dr. Sang | TREATMENT OF NEUROPATHIC PAIN WITH ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTOR (NMDA). |
| ITMI20011308A1 (en) * | 2001-06-21 | 2002-12-21 | Nicox Sa | DRUGS FOR CHRONIC PAIN |
| NZ531586A (en) | 2001-09-03 | 2005-09-30 | Newron Pharm Spa | Pharmaceutical composition comprising gabapentin or an analogue thereof and an alpha-aminoamide and its analgesic use |
| US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| US20060159743A1 (en) * | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
| TWI312285B (en) * | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US20060167032A1 (en) * | 2002-01-16 | 2006-07-27 | Galer Bradley S | Pharmaceutical composition and method for treating disorders of the central nervous system |
| AU2003211102B2 (en) * | 2002-02-13 | 2010-03-04 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating vascular disease |
| BR0307951A (en) * | 2002-02-26 | 2004-12-21 | Ortho Mcneil Pharm Inc | Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents. |
| US8097585B2 (en) | 2002-04-15 | 2012-01-17 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation |
| PL375161A1 (en) * | 2002-06-21 | 2005-11-28 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
| US8637512B2 (en) * | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
| AU2003260336C1 (en) * | 2002-07-29 | 2008-05-29 | Glaxo Group Limited | Sustained release formulations comprising lamotrigine |
| AU2003297639A1 (en) * | 2002-12-02 | 2004-06-23 | University Of Florida | Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases |
| HUP0300929A3 (en) * | 2003-04-09 | 2005-06-28 | Richter Gedeon Vegyeszet | Analgetic and/or muscle relaxant pharmaceutical composition |
| US20050124701A1 (en) * | 2003-06-11 | 2005-06-09 | Went Gregory T. | Method of targeting a therapeutic agent |
| US20040265364A1 (en) * | 2003-06-25 | 2004-12-30 | Binnur Ozturk | Neuropathy cream |
| JP2007512350A (en) * | 2003-11-25 | 2007-05-17 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | Carvedilol composition treatment and delivery methods |
| CA2554959A1 (en) * | 2004-01-29 | 2005-08-11 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions |
| WO2005079773A2 (en) * | 2004-02-13 | 2005-09-01 | Neuromolecular, Inc. | Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders |
| AR049646A1 (en) * | 2004-06-16 | 2006-08-23 | Janssen Pharmaceutica Nv | USEFUL SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS |
| MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
| US20060034910A1 (en) * | 2004-08-09 | 2006-02-16 | Sanjay Patel | Pharmaceutical composition for extended release of phenytoin sodium |
| MX2007002309A (en) * | 2004-08-24 | 2007-10-08 | Johnson & Johnson | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents. |
| PT1809271E (en) * | 2004-09-10 | 2010-08-30 | Newron Pharm Spa | Use of (r)-(halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators |
| EP1827385B1 (en) | 2004-11-23 | 2013-03-27 | Adamas Pharmaceuticals, Inc. | Pharmaceutical composition comprising memantine in an extended dosage release form for use in the treatment of dementias |
| US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| EP2623099A1 (en) | 2004-11-24 | 2013-08-07 | Neuromolecular Pharmaceuticals, Inc | Composition and method for treating neurological disease |
| WO2006121560A2 (en) | 2005-04-06 | 2006-11-16 | Adamas Pharmaceuticals, Inc. | Methods and compositions for treatment of cns disorders |
| US20060270742A1 (en) * | 2005-05-02 | 2006-11-30 | Jane Staunton | Compositions and methods for the treatment of neurodegenerative diseases |
| WO2006122035A2 (en) * | 2005-05-06 | 2006-11-16 | University Of Maryland, Baltimore | Method for treating central pain syndrome or for inducing centrally generated pain in an animal model |
| CA2609185A1 (en) | 2005-05-20 | 2006-11-30 | Ahmed F. Abdel-Magid | Process for preparation of sulfamide derivatives |
| EP2465499A3 (en) | 2005-06-27 | 2013-02-13 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for treating pain |
| US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
| US20070155827A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
| AR058389A1 (en) | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | USE OF SULFAMIDE BENZO-FUSED HETEROCICLIC DERIVATIVES FOR THE TREATMENT OF OBESITY |
| US20070155823A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents |
| US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
| US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| RS54522B1 (en) * | 2005-12-22 | 2016-06-30 | Newron Pharmaceuticals S.P.A. | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators |
| US20090176882A1 (en) | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| US20070191461A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine |
| US20070191449A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression |
| US20070191452A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain |
| US20070191474A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine |
| WO2007120485A2 (en) * | 2006-03-30 | 2007-10-25 | Cinergen, Llc | Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor |
| EP2026790A2 (en) | 2006-05-19 | 2009-02-25 | Janssen Pharmaceutica, N.V. | Co-therapy for the treatment of epilepsy and related disorders |
| ES2526398T3 (en) * | 2006-12-22 | 2015-01-12 | Allergan, Inc. | Serotonin-norepinephrine reuptake inhibitor compositions to treat chronic pain |
| US20120083508A1 (en) | 2006-12-22 | 2012-04-05 | Allergan, Inc. | Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain |
| CN101815518B (en) * | 2007-06-29 | 2013-01-09 | 埃莫里大学 | NMDA receptor antagonists for neuroprotection |
| JP5452494B2 (en) * | 2007-10-09 | 2014-03-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | A pharmaceutical composition for the treatment of neuropathic pain conditions comprising benfotiamine and one or more pharmaceutically active agents |
| US20090247617A1 (en) * | 2008-03-26 | 2009-10-01 | Abdel-Magid Ahmed F | Process for the preparation of benzo-fused heteroaryl sulfamates |
| US20090247616A1 (en) * | 2008-03-26 | 2009-10-01 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety |
| US20090247644A1 (en) * | 2008-03-28 | 2009-10-01 | Forest Laboratories Holdings Limited | Memantine formulations |
| MX2011000090A (en) | 2008-06-23 | 2011-03-02 | Janssen Pharmaceutica Nv | Disposable patch and reusable sensor assembly for use in medical device localization and mapping systems. |
| US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
| CA2738468A1 (en) * | 2008-09-27 | 2010-04-01 | Taraxos Inc. | Topical formulations for treatment of neuropathy |
| BR112012013487A2 (en) | 2009-12-02 | 2017-10-03 | Adamas Pharmaceuticals Inc | AMANTADINE COMPOSITIONS AND METHODS OF USE |
| US20110251239A1 (en) | 2010-04-07 | 2011-10-13 | Eisai Inc. | Combination therapy for the treatment of dementia |
| FR2998892B1 (en) | 2012-12-04 | 2015-01-02 | Pf Medicament | AMINOCYCLOBUTANE DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR USE AS MEDICAMENTS |
| US10154971B2 (en) | 2013-06-17 | 2018-12-18 | Adamas Pharma, Llc | Methods of administering amantadine |
| CA3195252A1 (en) | 2013-12-24 | 2015-07-02 | Durect Corporation | Uses of oxygenated cholesterol sulfates (ocs) |
| WO2018106108A1 (en) | 2016-12-06 | 2018-06-14 | KEPPEL HESSELING, Jan Marius | Topical pharmaceutical composition containing phenytoin and a (co -)an algesic for the treatment of chronic pain |
| FI3551166T3 (en) | 2016-12-06 | 2024-10-04 | Topical Innovations B V | Topical phenytoin for use in the treatment of peripheral neuropathic pain |
| CA3093401A1 (en) * | 2018-04-16 | 2019-10-24 | Biogen Ma Inc. | Methods of treating neuropathic pain |
| WO2020054872A1 (en) * | 2018-09-14 | 2020-03-19 | 国立大学法人富山大学 | Therapeutic agent for acute herpes zoster pain |
| JP2023524522A (en) | 2020-05-01 | 2023-06-12 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． | E protein channel blockers and ORF3 inhibitors as anti-COVID-19 agents |
| WO2022113069A1 (en) | 2020-11-24 | 2022-06-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | E protein channel blockers and orf3 inhibitors as anti-covid-19 agents |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4694010A (en) * | 1985-08-16 | 1987-09-15 | New York University | Anticonvulsant compositions and method |
| US4906638A (en) * | 1987-12-22 | 1990-03-06 | Nova Pharmaceutical Corporation | Dextromethorphan potentiator for anticonvulsant composition and method |
| JPH02502546A (en) * | 1987-12-22 | 1990-08-16 | ファーカニー、ジョン ダブリュ | Dextrorphan synergistic agent for anti-convulsant compositions and methods |
| US5075114A (en) * | 1990-05-23 | 1991-12-24 | Mcneil-Ppc, Inc. | Taste masking and sustained release coatings for pharmaceuticals |
| US5234929A (en) * | 1992-07-20 | 1993-08-10 | William Chelen | Method of treating motion sickness with anticonvulsants and antitussive agents |
| CA2115792C (en) * | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
| AU4078897A (en) * | 1996-08-23 | 1998-03-06 | Algos Pharmaceutical Corporation | Anticonvulsant containing composition for treating neuropathic pain |
| US6057373A (en) * | 1997-05-22 | 2000-05-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists |
-
1997
- 1997-08-21 AU AU40788/97A patent/AU4078897A/en not_active Abandoned
- 1997-08-21 AT AT97938475T patent/ATE293458T1/en not_active IP Right Cessation
- 1997-08-21 EP EP97938475A patent/EP0942752B1/en not_active Expired - Lifetime
- 1997-08-21 WO PCT/US1997/014680 patent/WO1998007447A1/en active IP Right Grant
- 1997-08-21 DE DE69733081T patent/DE69733081T2/en not_active Expired - Lifetime
- 1997-08-21 JP JP10510942A patent/JP2001500121A/en active Pending
- 1997-08-21 ES ES97938475T patent/ES2241055T3/en not_active Expired - Lifetime
- 1997-08-21 CA CA002264182A patent/CA2264182A1/en not_active Abandoned
-
1999
- 1999-02-22 US US09/253,598 patent/US6187338B1/en not_active Expired - Lifetime
-
2001
- 2001-02-09 US US09/780,858 patent/US6406716B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1998007447B1 (en) | Anticonvulsant containing composition for treating neuropathic pain | |
| US6406716B2 (en) | Anticonvulsant containing composition for treating neuropathic pain | |
| CO5150189A1 (en) | ANALGESIC COMPOSITIONS THAT INCLUDE ANTIEPILEPTIC COMPOUNDS AND METHODS TO USE THEM | |
| IL257944A (en) | Methods of treating developmental disorders using pipradrol | |
| Østensen et al. | Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus | |
| EP0938305B8 (en) | Method of alleviating pain by means of combining tramadol with an nmda antagonist | |
| MX9504034A (en) | Medical administering forms containing tioctic acid, or tioctic acid solid salts having improved release and bioavailability. | |
| DK0888111T3 (en) | Modified-release dosage preparation with multiple units | |
| IL115871A0 (en) | A pharmaceutical composition containing a melt-extruded blend of components and a method for the preparation thereof | |
| ZA965969B (en) | Salts derived from amidine and cyclooxygenase inhibitor process for the preparation thereof their application as medicinal drugs and pharmaceutical compositions in which they are contained | |
| AU6244898A (en) | (d)-methadone, a nonopioid analgesic | |
| NZ292429A (en) | Combination of non-narcotic analgesic and nmda receptor antagonist for alleviating pain | |
| O'Brien et al. | Carprofen: a new nonsteroidal antiinflammatory drug pharmacology, clinical efficacy and adverse effects | |
| US4439452A (en) | Class of analgesics and/or anti-inflammatory agents consisting of inhibitors of breakdown of endogenous enkephalin and/or endorphin, and combinations of said analgesics with antipyretic, anti-inflammatory (aspirin-type) drugs | |
| SE9600041L (en) | Device for tightening a screw joint in a bone anchored dental implant | |
| FI956269A0 (en) | Use of ropivacaine in the manufacture of a pharmaceutical product having an analgesic effect and a slight lack of motor inhibition | |
| PL329036A1 (en) | Inclusive compounds of diclophenac and cyclodextrin | |
| CA2411960A1 (en) | Analgesic and anti-inflammatory compositions containing cox-2 inhibitors | |
| Reuben | Effect of nonsteroidal anti-inflammatory drugs on osteogenesis and spinal fusion | |
| BR0010373A (en) | Use of a copper agonist and method for identifying a copper agonist | |
| EP1051993A3 (en) | 5HT1 receptor agonists and either a COX-2 inhibitor or NSAID for the treatment of migraine | |
| PT862462E (en) | A NEW COMBINATION OF A BETA RECEPTOR BLOCKER AND AN OPIOID | |
| HUP0001889A3 (en) | Pharmaceutical compositions containing 5ht1 receptor agonists and a cox-2 inhibitor for treating migraine | |
| DIONNE | ORAL SURGERY AS A MODEL OF ACUTE PAIN AND INFLAMMATION | |
| RU97105186A (en) | ANALYTIC COMPOSITIONS CONTAINING A NON-DRUG ANALGETIC AND ANALGESIA AMPLIFIER |